Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

Type 2 Diabetes (T2D) Clinical Trial

Official title:
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes

Status Completed

Clinical Trial Summary

This study will test the safety and tolerability of omarigliptin. It is hypothesized that administration of once-weekly omarigliptin in obese but otherwise healthy participants, and in obese participants with Type 2 diabetes (T2D) will be sufficiently safe and well tolerated to permit continued clinical investigation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01088711
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Completed
Phase	Phase 1
Start date	March 11, 2010
Completion date	May 11, 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01478841` - Polyphenols and Insulin Resistance	N/A
Completed	`NCT02759289` - Arsenic, Disordered Glucose Homeostasis and Atherosclerosis
Completed	`NCT02957721` - Diabetes Engagement and Activation Platform	N/A
Completed	`NCT02726217` - NYULMC CareSmarts Pilot	N/A
Recruiting	`NCT04270656` - Liver and Metabolic Effects of Insulin Pump Therapy in Diabetics Type 2 With Non-alcoholic Hepatic Steatosis	N/A